| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/18/2011 | EP2322642A2 Arachidonic acid and methods for the production and use thereof |
| 05/18/2011 | EP2322641A2 Arachidonic acid and methods for the production and use thereof |
| 05/18/2011 | EP2322640A2 Arachidonic acid and methods for the production and use thereof |
| 05/18/2011 | EP2322628A2 Mutations in the BCR-ABL tyrosine kinase associated with resistance to STI-571 |
| 05/18/2011 | EP2322627A2 Mutations in the BCR-abl tyrosine kinase associated with resistance to STI-571 |
| 05/18/2011 | EP2322618A1 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells |
| 05/18/2011 | EP2322615A1 Use of unmethylated CpG oligonucleotides for the treatment of allergy |
| 05/18/2011 | EP2322535A2 Riboswitches, methods for their use, and compositions for use with riboswitches |
| 05/18/2011 | EP2322534A1 Antiviral nucleosides |
| 05/18/2011 | EP2322529A1 Selective glycosidase inhibitors and uses thereof |
| 05/18/2011 | EP2322528A1 Stemonamide synthesis intermediate and pharmaceutical composition for prevention and/or treatment of cancer |
| 05/18/2011 | EP2322527A1 Triazole derivatives |
| 05/18/2011 | EP2322525A1 Purine derivatives for use as adenosin A2A receptor agonists |
| 05/18/2011 | EP2322523A1 Pyridopyrimidinone Inhibitors of PI3Kalpha |
| 05/18/2011 | EP2322522A1 New tiotropium salts, processes for their preparation and drug formulations containing them |
| 05/18/2011 | EP2322521A1 Heteroaryl compounds useful as inhibitors of GSK-3 |
| 05/18/2011 | EP2322520A1 Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia |
| 05/18/2011 | EP2322518A1 Method of manufacture of 1,3-dioxolane and 1,3-oxathiolane nucleosides |
| 05/18/2011 | EP2322517A1 Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (MTC) |
| 05/18/2011 | EP2322513A2 Intermediates |
| 05/18/2011 | EP2322510A2 8-substituted benzoazepines as toll-like receptor modulators |
| 05/18/2011 | EP2322509A1 Azapeptide derivatives as HIV protease inhibitors |
| 05/18/2011 | EP2322507A1 Matrix metalloproteinase inhibitors |
| 05/18/2011 | EP2322506A1 Histamine H3 receptor agents, preparation and therapeutic uses |
| 05/18/2011 | EP2322505A1 1-adamantylazetidin-2-one derivative and pharmaceutical preparation comprising same |
| 05/18/2011 | EP2322501A1 4-dedimethylamino tetracycline compounds |
| 05/18/2011 | EP2322500A1 Fluoro-labeled homo-glutamate derivatives and precursors thereof |
| 05/18/2011 | EP2322470A2 Method for manufacturing uniform size polymeric nanoparticles containing poorly soluble drugs |
| 05/18/2011 | EP2322244A1 Pharmaceutical composition suitable for the treatment of malaria within one day |
| 05/18/2011 | EP2322243A1 Pharmaceutical products and compositions comprising formoterol, ciclesonide and tiotropium |
| 05/18/2011 | EP2322226A2 Solutions and methods for inhibition of pain, inflammation and cartilage degradation |
| 05/18/2011 | EP2322225A1 Selective norepinephrine serotonin reuptake inhibitors for treating fibromyalgia syndrome, chronic fatigue syndrome and pain |
| 05/18/2011 | EP2322224A1 Potentiator of activity of anti-cancer agent and use thereof, and biomarker for prediction of prognosis in cancer patient and use thereof |
| 05/18/2011 | EP2322223A1 Therapeutic agent for migraine |
| 05/18/2011 | EP2322222A1 Therapeutic agent for irritable bowel syndrome |
| 05/18/2011 | EP2322212A1 Compositon of antigen and glycolipid adjuvant for sublingual administration |
| 05/18/2011 | EP2322210A1 Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| 05/18/2011 | EP2322209A2 Tumor specific oligosaccharide epitopes and use thereof |
| 05/18/2011 | EP2322199A1 Growth differentiation factor receptors, and methods of using same |
| 05/18/2011 | EP2322190A1 Compositions for bowel cleansing and use thereof |
| 05/18/2011 | EP2322189A2 Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants |
| 05/18/2011 | EP2322188A1 Treatment of Inflammatory and Hyperproliferative Skin disease |
| 05/18/2011 | EP2322187A2 Use of uridine in combination with choline for the treatment of memory disorders |
| 05/18/2011 | EP2322186A2 Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
| 05/18/2011 | EP2322185A2 Polynucleotide therapy |
| 05/18/2011 | EP2322184A1 Compositions for alleviating premenstrual syndrome symptoms |
| 05/18/2011 | EP2322183A1 Use of prodrugs for ocular intravitreous administration |
| 05/18/2011 | EP2322182A1 Androstenol derivatives as androgen receptor modulator |
| 05/18/2011 | EP2322181A2 A pentoxifilin-based dermatological pharmaceutical composition, for topical application, in cream, gel, ointment, solution, emulsion, liposome and microcapsule form |
| 05/18/2011 | EP2322180A1 Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery |
| 05/18/2011 | EP2322179A1 Pharmaceutical Compositions Comprising Dextromethorphan and Quinidine for the Treatment of Neurological Disorders |
| 05/18/2011 | EP2322178A2 Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia |
| 05/18/2011 | EP2322177A1 Use of a preparation based on nifedipine for treating vaginismus |
| 05/18/2011 | EP2322176A1 New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives |
| 05/18/2011 | EP2322175A1 Pharmaceutical composition for treating hypertension and metabolic syndrome and use thereof |
| 05/18/2011 | EP2322174A2 Combined use of valsartan and calcium channel blockers for therapeutic purposes |
| 05/18/2011 | EP2322173A1 Cationic bacteriochlorophyll derivatives and uses thereof |
| 05/18/2011 | EP2322172A1 Use of celivarone for preparing a medicament for the treatment of patients with arrhythmia and having an increase of creatinine level due to celivarone administration |
| 05/18/2011 | EP2322171A2 Fluorine labeled L-glutamic acid derivatives |
| 05/18/2011 | EP2322170A1 Minimizing adverse experience associated with oxybutynin therapy |
| 05/18/2011 | EP2322169A1 Composition containing a DHA oil for use in the treatment of cystic fibrosis |
| 05/18/2011 | EP2322168A1 Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments |
| 05/18/2011 | EP2322167A1 Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments |
| 05/18/2011 | EP2322166A1 Methods and compositions for reduction of side effects of therapeutic treatments |
| 05/18/2011 | EP2322165A1 Apo2 ligand/TRAIL formulations |
| 05/18/2011 | EP2322164A2 Carbonylamino derivatives useful for the treatment of inflammatory bowel disease |
| 05/18/2011 | EP2322163A1 New therapeutics approaches for treating alzheimer disease |
| 05/18/2011 | EP2322162A1 5HT2C receptor modulator compositions and methods of use |
| 05/18/2011 | EP2322161A1 Composition for preventing and treating odontostomatological pathologies of animals |
| 05/18/2011 | EP2322160A1 Methods of inducing terminal differentiation |
| 05/18/2011 | EP2322159A1 Use of pterostilbene (pter) as medicament for prevention and/or treatment of skin diseases, damages or injures or as cosmetic |
| 05/18/2011 | EP2322158A2 Resveratrol and/or grape leaf extract for energy metabolism activation |
| 05/18/2011 | EP2322157A1 Composition for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
| 05/18/2011 | EP2322156A1 Composition for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level |
| 05/18/2011 | EP2322155A1 Use of HIF alpha stabilizers for enhancing erythropoiesis |
| 05/18/2011 | EP2322154A2 Methods for detecting and clearing cross beta structure comprising proteins with crossbeta structure binding compounds. |
| 05/18/2011 | EP2322153A1 Use of HIF Alpha stabilizers for enhancing erythropoiesis |
| 05/18/2011 | EP2322152A1 Method of preparing a composition comprising a GPR119 agonist |
| 05/18/2011 | EP2322151A2 Sustained release formulation comprising a GPR119 agonist and a DPP-IV inhibitor |
| 05/18/2011 | EP2322150A2 Method of identifying GLP-1 secretagogues |
| 05/18/2011 | EP2322149A1 Methods and compositions for the treatment of ischemia |
| 05/18/2011 | EP2322146A2 Microcapsule formulations comprising two pharmaceutically active ingredients |
| 05/18/2011 | EP2322143A1 Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes |
| 05/18/2011 | EP2322137A1 Stable hydroalcoholic compositions |
| 05/18/2011 | EP2321414A1 Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand |
| 05/18/2011 | EP2321346A1 Methods and substances for stimulating muscle regeneration |
| 05/18/2011 | EP2321334A1 New no releasing steroids derivatives |
| 05/18/2011 | EP2321333A1 New no-releasing steroids for the treatment of retina and macula lutea diseases |
| 05/18/2011 | EP2321332A1 Self-avoiding molecular recognition systems in dna amplification |
| 05/18/2011 | EP2321331A2 Modulation of myeloid differentation primary response gene 88 (myd88) expression by antisense oligonucleotides |
| 05/18/2011 | EP2321329A2 Novel glucopyranose derivatives, preparation thereof, and biological uses thereof |
| 05/18/2011 | EP2321328A1 Mimetics of sulfated oligosaccharides |
| 05/18/2011 | EP2321325A1 Antitumoral macrolides |
| 05/18/2011 | EP2321324A1 Crystalline forms of a pyridine derivative |
| 05/18/2011 | EP2321323A1 Dimeric derivatives of artemisinin and application in anti-cancer therapy |
| 05/18/2011 | EP2321322A1 Streptospirole derivatives |
| 05/18/2011 | EP2321321A1 Triazolo [4, 5-d]pyramidine derivatives and their use as purine receptor antagonists |
| 05/18/2011 | EP2321320A1 Novel compounds and their uses in diagnosis |
| 05/18/2011 | EP2321319A1 Antiviral compounds |
| 05/18/2011 | EP2321318A1 Pyrazolopyridine kinase inhibitors |